Milrinone Via Lumbar Subarachnoid Catheter for Vasospasm After Aneurysmal Subarachnoid Hemorrhage
- 823 Downloads
Delayed ischemic neurological deficit (DIND) due to symptomatic vasospasm is a major cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). The aim of this study was to elucidate the safety and feasibility of intrathecal milrinone infusion via lumber subarachnoid catheter for prevention of DIND after aSAH.
We diagnosed 425 consecutive patients with aSAH who received clipping or coil embolization within 48 h after arrival. Patients with the evidence of vasospasm on CT angiography (CTA) received the milrinone therapy via lumbar subarachnoid catheter. DIND, delayed cerebral infarction (DCI), and modified Rankin scale at 3 months after SAH were used for the assessment of outcome.
Of 425 patients, 170 patients (40.0 %) with CTA-proven vasospasm received the milrinone therapy. DIND was observed in 68 patients (16.0 %), DCI in 30 patients (7.1 %), and the overall mortality was 7.2 %. In patients with WFNS grade IV and V aSAH, 26 out of 145 patients (17.9 %) were presented with DIND, 12 (8.3 %) with DCI, and the mortality was 16.0 %. No major complication related to the milrinone injection was observed.
Intrathecal milrinone injection via lumbar catheter was safe and feasible, and further randomized prospective studies are needed to confirm the effectiveness of this regimen in the patients with SAH.
KeywordsIntracranial aneurysm Milrinone Subarachnoid hemorrhage Vasospasm Treatment Intrathecal injection
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Kimball MM, Velat GJ, Hoh BL. Participants in the international multi-disciplinary consensus conference on the critical care management of subarachnoid hemorrhage. Critical care guidelines on the endovascular management of cerebral vasospasm. Neurocrit Care. 2011;15:336–41.PubMedCrossRefGoogle Scholar
- 9.Nishibuchi M, Ono S, Iseda K, Manabe H, Hishikawa T, Date I. Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone. Neurosurgery. 2010;66:158–64.CrossRefGoogle Scholar
- 15.Shirao S, Yoneda H, Ishihara H, Kajiwara K, Suzuki M; Survey Study Members of Japan Neurosurgical Society. A proposed definition of symptomatic vasospasm based on treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan: consensus 2009, a project of the 25 Spasm Symposium. Surg Neurol Int. 2011;2:74.Google Scholar
- 21.Lannes M, Teitelbaum J, del Pilar Cortés M, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16:354–62.Google Scholar
- 22.Taki W, Sakai N, Suzuki H; PRESAT Group. Determinants of poor outcome after aneurysmal subarachnoid hemorrhage when both clipping and coiling are available: Prospective Registry of Subarachnoid Aneurysms Treatment (PRESAT) in Japan. World Neurosurg. 2011;76:437–45.Google Scholar
- 23.Molyneux A, Kerr R, Stratton I, International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. 2002;360:1267–74.PubMedCrossRefGoogle Scholar
- 24.Nieuwkamp DJ, Vaartjes I, Algra A, Bots ML, Rinkel GJ. Age- and gender-specific time trend in risk of death of patients admitted with aneurysmal subarachnoid hemorrhage in the Netherlands. Int J Stroke. 2013;8 Suppl A100:90–4.Google Scholar
- 25.Treggiari MM; Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Hemodynamic management of subarachnoid hemorrhage. Neurocrit Care. 2011;15:329–35.Google Scholar